UCL (London, UK) researchers have demonstrated that levels of neurofilament protein in the blood are raised in Huntington’s patients and carriers of the disease.
Browsing: prognostic biomarker
The Systemic Synuclein Sampling Study (S4) is uniquely designed to identify a reproducible diagnostic and progression biomarker for Parkinson’s disease.
Researchers report a correlation between higher plasma levels of tau protein and a longer recovery time in athletes with sport-related concussion.
A recent study has identified a potential genetic biomarker, SHOX2, for predicting the survival of patients with diffuse glioma brain tumors.
Ahead of its annual congress, The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) has previewed key sessions at the 32nd edition of the world’s largest congress on multiple sclerosis, taking place from 14–17 September 2016 in London, UK.
Researchers have identified a new biomarker for Parkinson’s disease in patient urine samples – the biomarker could be used in the future to monitor disease progression and treatment success.